Industry Trend Analysis - Gilead Partners With Pfizer To Maximise Revenue From Kite Purchase - MAR 2018
BMI View: Kite ' s collaboration with Pfizer to enhance Yescarta treatment outcome with a combination is an attempt to maximise the product ' s market value. High prospective competition in the market will limit sales, as Gilead ' s revenue continues to decline after losing its HCV patient pool.
Kite, a Gilead Sciences company, has announced the initiation of a clinical trial collaboration with Pfizer. The aim is to evaluate the safety and efficacy of the investigational combination of Yescarta (axicabtagene ciloleucel) and Pfizer's utomilumab in patients with refractory large B-cell lymphoma. Yescarta is a CAR-T cell therapy. It is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of adults with relapsed or refractory (r/r) large B-cell lymphoma (DLBCL). Utomilumab is a fully humanised 4-1BB agonist monoclonal antibody that has been shown in preclinical models to enhance T-cell mediated immune responses. Adding this compound to the treatment could potentially enhance T-cell proliferation and activity by augmenting the CD28 costimulatory domain of Yescarta with exogenous 4-1BB signalling. A multicentre Phase I/II study sponsored by Kite is expected to begin in 2018 to evaluate this combination, or similar combinations between Kite's engineered T-cell products and utomilumab.
Yescarta Sales To Increase Dramatically By 2025
|Yescarta Revenue to Rise Significantly By 2025|
|Yescarta Sales Forecast (USDmn)|
|e = estimate. Source: Bloomberg, BMI|